Announcements Trials
Browse Landscape

Clinical Trials

2 trials
RecentStart dateEnrollment
HA 22 × Clear all

Phase

Phase 2 1

Status

Terminated 1Approved for marketing 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

Cisplatin 3180Cyclophosphamide 3173Carboplatin 2960Radiotherapy 2772Paclitaxel 2708Gemcitabine 2552pembrolizumab 2370Bevacizumab 2195Docetaxel 2191Fluorouracil 1839Capecitabine 1815Oxaliplatin 1724Dexamethasone 1593Nivolumab 1577Doxorubicin 1501Rituximab 1480Magnetic Resonance Spectroscopy 1368Etoposide 1344Irinotecan 1241Leucovorin 1217Drug Therapy 1190Cytarabine 1127Pemetrexed 1068fludarabine 1035Specimen Handling 987Vincristine 964Prednisone 940Cetuximab 939Trastuzumab 937Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03501615 2020-06-29

MOXE

AstraZeneca

Approved for marketing
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT02338050 2015-09-16

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Center for International Blood and Marrow Transplant Research

Phase 2 Terminated
1 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡